Cited by

• Mechlorethamine Hydrochloride Gel in the Treatment of Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Focus on Patient Selection and Special Considerations.

  Crimp C, Gangal A, Tarabadkar ES, Shinohara MM. Crimp C, et al. Cancer Manag Res. 2022 Nov 22;14:3271-3279. doi: 10.2147/CMAR.S351420. eCollection 2022. Cancer Manag Res. 2022. PMID: 36444357 Free PMC article. Review.
• Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.

  Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, Hull CM, Knobler EH, Rook AH, Kim EJ, Naylor MF, Adelson DM, Kimball AB, Wood GS, Sundram U, Wu H, Kim YH. Lessin SR, et al. JAMA Dermatol. 2013 Jan;149(1):25-32. doi: 10.1001/2013.jamadermatol.541. JAMA Dermatol. 2013. PMID: 23069814 Free PMC article. Clinical Trial.
• Randomized Mechlorethamine/Chlormethine Induced Dermatitis Assessment Study (MIDAS) Establishes Benefit of Topical Triamcinolone 0.1% Ointment Cotreatment in Mycosis Fungoides.

  Alexander-Savino CV, Chung CG, Gilmore ES, Carroll SM, Poligone B. Alexander-Savino CV, et al. Dermatol Ther (Heidelb). 2022 Mar;12(3):643-654. doi: 10.1007/s13555-022-00681-6. Epub 2022 Feb 5. Dermatol Ther (Heidelb). 2022. PMID: 35122614 Free PMC article.
• STING expression is an independent prognostic factor in patients with mycosis fungoides.

  Takayanagi-Hara R, Sawada Y, Sugino H, Minokawa Y, Kawahara-Nanamori H, Itamura M, Tashiro T, Kaneoka A, Saito-Sasaki N, Yamamoto K, Okada E. Takayanagi-Hara R, et al. Sci Rep. 2022 Jul 26;12(1):12739. doi: 10.1038/s41598-022-17122-1. Sci Rep. 2022. PMID: 35882970 Free PMC article.